
05/12/2024 Funding
VIVEbiotech Secures Growth Investment from Ampersand Capital Partners to Expand Lentiviral Vector Development and Manufacturing Capabilities
Support the execution of a robust pipeline of customer projects for innovators developing groundbreaking in vivo and ex vivo cell and gene therapies.

01/11/2021 Entrepreneurship
‘Syngoi Technologies’: Columbus VP creates a new company in Bizkaia for synthetic DNA production
Columbus VP, a venture capital investment management company with a singular focus on business opportunities emerging in the biotechnology and life sciences sector.

28/01/2019 Entrepreneurship
Columbus launches a €70 million fund for biomedicine
With the new investment fund, the managers plan to build two new plants in San Sebastian